Trials / Completed
CompletedNCT01573273
Oxytocin in Cocaine Dependence
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Stress is likely involved in relapse to cocaine use. This project will investigate the role oxytocin may play in the stress response in cocaine-dependent men and women and examine how oxytocin may impact brain activity in individuals exposed to cocaine-related cues.
Detailed description
Stress is an important predictor of relapse, and targeting stress-activated pathways may lead to therapeutic advancements in the treatment of substance use disorders. Oxytocin has been shown to promote trust, social bonding, and calmness; however, its potential effects have not been explored in cocaine-dependent individuals. Oxytocin receptors have been localized to brain regions that are activated by drug-paired cues and preclinical studies have shown that oxytocin attenuates the acute and long-term behavioral effects of psychostimulants. However, little is known about the role of oxytocin in mediating the affective response to cocaine-paired cues and associated neural activity in cocaine-dependent men and women. This project is a direct evolution from our previous SCOR-supported research. Our work has progressed from characterizing sex/gender differences in response to social stressors and cocaine cues in cocaine-dependent men and women, to our on-going work evaluating whether stress potentiates cue-induced craving and the impact of hormones on this response. The proposed study will investigate the role of oxytocin in the sex/gender differences in stress response and craving in cocaine-dependent individuals and preliminarily explore its therapeutic potential.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxytocin | intranasal administration, 40 IUs |
| DRUG | Saline | intranasal administration, 40 IUs |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2017-12-19
- Completion
- 2017-12-19
- First posted
- 2012-04-09
- Last updated
- 2019-03-13
- Results posted
- 2019-03-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01573273. Inclusion in this directory is not an endorsement.